Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

Journal for ImmunoTherapy of Cancer

Volumn 1, Issue , 2013, Pages

  Stroncek, David F ^a   Melief, Cornelis J M ^b   Castiello, Luciano ^a   Cesano, Alessandra ^c   Cheever, Martin A ^d   Civini, Sara ^a   Comin Anduix, Begonya ^e   Gajewski, Thomas F ^f   Greenberg, Philip D ^g   Kalinski, Pawel ^h,i,j   Kaufman, Howard L ^k   Kershaw, Michael H ^l   Khleif, Samir N ^m   Marincola, Francesco ⁿ   Merritt, William ^o   Munn, David H ^m   Powell, Daniel J ^p   Restifo, Nicholas P ^o   Rosenberg, Steven A ^o   Puri, Raj K ^q   Streicher, Howard ^o   Szalay, Aladar A ^r   Yee, Cassian ^s   Zitvogel, Laurence ^t   Ribas, Antoni ^e   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Nodality Inc   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j University of Pittsburgh   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l PETER MACCALLUM CANCER CENTRE   (Australia)

^m MEDICAL COLLEGE OF GEORGIA   (United States)

ⁿ SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^o NATIONAL CANCER INSTITUTE   (United States)

^p UNIVERSITY OF PENNSYLVANIA   (United States)

^q CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^r GENELUX CORPORATION   (United States)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^t INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Adoptive cellular therapy; Cancer; Immunotherapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ADXS11 001; BACTERIAL VACCINE; BORTEZOMIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACINOSTAT; DENDRITIC CELL VACCINE; DURVALUMAB; FALIMAREV; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 15; IPILIMUMAB; METRONIDAZOLE; MICRORNA 124; ONCOLYTIC VIRUS; POXVIRUS VECTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; FLOW CYTOMETRY; GENETIC ENGINEERING; GLIOMA; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MELANOMA; MESOTHELIOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE CELL ANALYSIS; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

EID: 84991030104     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-1-4     Document Type: Article

References (64)

1. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
2. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL: Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 2010, 5:e11469.
3. Johnson TS, Munn DH: Host indoleamine 2, 3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest 2012, 41:765-797.
4. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al: Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004, 114:280-290.
5. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, et al: PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64:1140-1145.
6. Westwood JA, Darcy PK, Guru PM, Sharkey J, Pegram HJ, Amos SM, et al: Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med 2010, 8:42.
7. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, et al: 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012, 2:765.
8. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004, 101:1969-1974.
9. Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, et al: Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood 2012, 120:e1-e8.
10. Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, et al: New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 2012, 10:48.
11. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al: Durable complete responses in heavily pretreted patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
12. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, et al: Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012, 109:4592-4597.
13. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al: CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010, 16:6122-6131.
14. Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, et al: Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 2012, 35:283-292.
15. Ye Q, Loisiou M, Levine BL, Suhoski MM, Riley JL, June CH, et al: Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J Transl Med 2011, 9:131.
16. Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, et al: The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 2012, 4:149ra120.
17. Radvanyi LG, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, et al: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012, 18:6758-6770.
18. Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, et al: Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012, 119:5688-5696.
19. Li Y, Yee C: IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 2008, 111:229-235.
20. Li Y, Bleakley M, Yee C: IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005, 175:2261-2269.
21. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al: Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A 2012, 109:1210-1215.
22. Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, et al: Evaluation of gamma-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother 2012, 35:430-439.
23. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al: IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011, 121:4746-4757.
24. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al: Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010, 70:6725-6734.
25. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924.
26. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
27. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al: B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor-transduced T cells. Blood 2012, 119:2709-2720.
28. Porter DL, Levine BL, Kalos M, Bagg A, June CH: Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
29. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
30. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M: Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2012, 31:71-75.
31. Hanada K, Restifo NP: Double or nothing on cancer immunotherapy. Nat Biotechnol 2013, 31:33-34.
32. Gattinoni L, Klebanoff CA, Restifo NP: Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012, 12:671-684.
33. Restifo NP, Dudley ME, Rosenberg SA: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
34. Klebanoff CA, Gattinoni L, Restifo NP: Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother 2012, 35:651-660.
35. Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, et al: IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111:5326-5333.
36. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al: Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011, 71:3516-3527.
37. Wolfl M, Merker K, Morbach H, Van Gool SW, Eyrich M, Greenberg PD, et al: Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol Immunother 2011, 60:173-186.
38. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, et al: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012, 118:4354-4362.
39. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, der Berends-van Meer DM, Vloon AP, et al: Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008, 14:169-177.
40. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Der Berends-van Meer DM, et al: Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008, 14:178-187.
41. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Der Berends-van Meer DM, Vloon AP, et al: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
42. Melief CJ: Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine. J Immunother 2012, 35:215-216.
43. Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, Kirkwood JM, et al: Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol 2010, 184:591-597.
44. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al: Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 29:330-336.
45. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, et al: NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012, 72:3735-3743.
46. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et al: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999, 6:409-422.
47. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC Jr, Mulholland SG, Lattime EC: Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001, 166:1291-1295.
48. Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, et al: Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res 2012, 72:4753-4764.
49. Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, et al: Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 2012, 30:337-343.
50. Wallecha A, French C, Petit R, Singh R, Amin A, Rothman J: Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol 2012, 201(2):542851.
51. Sutton VR, Sedelies K, Dewson G, Christensen ME, Bird PI, Johnstone RW, et al: Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. Cell Death Dis 2012, 3:e344.
52. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, et al: Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009, 69:8693-8699.
53. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, et al: BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012, 72:3928-3937.
54. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
55. Dematteo RP: Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST). J Gastrointest Surg 2012, 16:1645-1647.
56. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al: Long-term results from a randomized phase II trial of standardversus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625.
57. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebocontrolled trial. Lancet 2009, 373:1097-1104.
58. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, et al: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK celldependent antitumor effects. J Clin Invest 2004, 114:379-388.
59. Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, et al: Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009, 69:3563-3569.
60. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, et al: Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011, 17:700-707.
61. Cesano A, Parkinson D: Applications of multiparametric flow cytometry: providing new insights into biology to bridge the gap between research discovery and clinical application. Cytometry A 2012, 81:732-733.
62. Longo DM, Louie B, Putta S, Evensen E, Ptacek J, Cordeiro J, et al: Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age-and race-associated differences in immune signaling pathway activation. J Immunol 2012, 188:1717-1725.
63. Bendall SC, Simonds EF, Qiu P, Amir E, Krutzik PO, Finck R, et al: Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332:687-696.
64. Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV, et al: Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol 2012, 30:858-867.